Cullinan Therapeutics (CGEM) FCF Payout Ratio (2024)
Cullinan Therapeutics (CGEM) posted quarterly FCF Payout Ratio of 0.02 for Q3 2024, up 81.61% quarter-over-quarter from 0.1 in Q2 2024.
Powered by 
Analysis
Cullinan Therapeutics (CGEM) FCF Payout Ratio (2024) Analysis & Trends
Cullinan Therapeutics' FCF Payout Ratio history runs 1 years deep, the most recent figure standing at 0.02 for Q3 2024.
- In Q3 2024, FCF Payout Ratio changed N/A year-over-year to 0.02; the TTM figure through Dec 2025 stood at 0.0 (up 87.81% YoY), while the FY2024 annual figure was 0.03, changed N/A from the prior year.
- FCF Payout Ratio for Q3 2024 stood at 0.02, up from 0.1 in the prior quarter.
- The five-year high for FCF Payout Ratio was 0.02 in Q3 2024, with the low at 0.1 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.17 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.07 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Cullinan Therapeutics | 1.37 Bn | 1.37 Bn | - | - |